patritumab
daiichi sankyo
['breast', 'bcsm', 'patritumab']
according to ian e. krop, md, phd, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with her3-expressing metastatic breast cancer, warranting further research. #asco22 #bcsm 
Oncology news and insights from leading researchers and cancer centers.